Research Progress and Challenges of CAR-T Cell Therapy for Solid Tumors
10.3971/j.issn.1000-8578.2026.25.0836
- VernacularTitle:实体瘤CAR-T疗法的研究进展与挑战
- Author:
Jun LU
1
;
Lisong TENG
1
Author Information
1. Department of Surgical Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310000, China.
- Publication Type:SPECIALFEATURE
- Keywords:
Solid tumor;
Chimeric antigen receptor T-cell therapy;
Tumor-associated antigen;
Tumor-specific antigen;
Tumor microenvironment;
Artificial intelligence;
Clinical trial
- From:
Cancer Research on Prevention and Treatment
2026;53(6):413-422
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T-cell (CAR-T) therapy, a revolutionary technology in tumor immunotherapy, has achieved breakthrough progress in the treatment of hematological malignancies. To date, multiple CAR-T products have been approved for clinical use worldwide, but progress in their application to solid tumor treatment has been slow mainly due to the highly complex biological characteristics of solid tumors. In recent years, the continuous identification of novel targets in solid tumors, continuous innovations in genetic engineering technologies, growing maturity of combination therapeutic strategies, and rapid advancement in artificial intelligence have expanded the potential applications of CAR-T therapy in solid tumor treatment, highlighting its broad translational prospects. This article systematically reviews recent clinical progress in CAR-T therapy for solid tumors, comprehensively analyzes core challenges and corresponding countermeasures, and outlines future directions.
